Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,319,985
  • Shares Outstanding, K 212,810
  • Annual Sales, $ 1,536 M
  • Annual Income, $ -313,140 K
  • 36-Month Beta 1.05
  • Price/Sales 9.32
  • Price/Cash Flow 77.39
  • Price/Book 7.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.31
  • Number of Estimates 2
  • High Estimate 0.37
  • Low Estimate 0.24
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +1,450.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.52 +7.69%
on 11/15/18
68.93 -3.89%
on 12/03/18
+2.10 (+3.27%)
since 11/14/18
3-Month
58.33 +13.58%
on 10/30/18
70.58 -6.13%
on 10/03/18
-1.84 (-2.70%)
since 09/14/18
52-Week
58.33 +13.58%
on 10/30/18
102.63 -35.45%
on 01/03/18
-29.72 (-30.97%)
since 12/14/17

Most Recent Stories

More News
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

AVEO : 1.95 (-2.01%)
ANIK : 30.23 (-3.05%)
VVUS : 2.81 (+1.08%)
INCY : 66.25 (-1.55%)
EXEL : 21.03 (-1.22%)
GILD : 65.57 (-2.64%)
AMGN : 192.07 (-2.76%)
Incyte to Present at Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:

INCY : 66.25 (-1.55%)
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being...

LLY : 111.93 (-2.55%)
INCY : 66.25 (-1.55%)
Look for Shares of Incyte Corp to Potentially Pullback after Yesterday's 3.81% Rise

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $66.65 to a high of $68.60. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $66.88...

INCY : 66.25 (-1.55%)
Incyte Corp Rises 3.81% on Heavy Volume: Watch For Potential Pullback

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $66.65 to a high of $68.60. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $66.88...

INCY : 66.25 (-1.55%)
Roche to Create Companion Diagnostic Test for Merck's Keytruda

Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.

MRK : 76.48 (-3.20%)
INCY : 66.25 (-1.55%)
RHHBY : 31.0900 (-2.54%)
BMY : 52.12 (-2.83%)
5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

CELG : 68.20 (-2.21%)
BMRN : 93.11 (-0.83%)
VRTX : 170.06 (-1.94%)
ALNY : 77.13 (+1.94%)
INCY : 66.25 (-1.55%)
SNY : 44.05 (-1.87%)
ALXN : 109.43 (-2.67%)
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study

AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.

AZN : 39.15 (-0.23%)
MRK : 76.48 (-3.20%)
INCY : 66.25 (-1.55%)
BMY : 52.12 (-2.83%)
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

AGN : 148.23 (-1.74%)
BMRN : 93.11 (-0.83%)
INCY : 66.25 (-1.55%)
SHPG : 174.95 (-0.98%)
Incyte (INCY) Announces Positive Data on Jakafi for GVHD

Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.

MRK : 76.48 (-3.20%)
LLY : 111.93 (-2.55%)
INCY : 66.25 (-1.55%)
NVS : 87.39 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 68.50
1st Resistance Point 67.37
Last Price 66.25
1st Support Level 65.39
2nd Support Level 64.54

See More

52-Week High 102.63
Fibonacci 61.8% 85.71
Fibonacci 50% 80.48
Fibonacci 38.2% 75.25
Last Price 66.25
52-Week Low 58.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar